1,355.20
-20.20
(-1.47%)
As of 2:51:53 PM GMT+5:30. Market Open.
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
129,417,100
116,354,560
114,319,380
121,741,980
108,060,260
Cost of Revenue
47,255,940
48,790,420
45,866,050
47,781,710
39,966,250
Gross Profit
82,161,160
67,564,140
68,453,330
73,960,270
68,094,010
Operating Expense
64,159,120
61,253,410
57,664,590
55,559,790
50,933,650
Operating Income
18,002,040
6,310,730
10,788,740
18,400,480
17,160,360
Net Non Operating Interest Income Expense
-2,827,360
-5,097,930
-3,420,360
-2,886,640
-3,504,660
Pretax Income
19,220,620
364,950
2,398,420
14,412,460
13,824,750
Tax Provision
21,179,520
18,673,450
3,294,030
4,475,970
4,123,870
Net Income Common Stockholders
-1,758,350
-15,016,680
2,972,450
9,417,110
9,700,380
Diluted NI Available to Com Stockholders
-1,758,350
-15,016,680
2,972,450
9,417,110
9,700,380
Basic EPS
-6.24
-53.22
10.53
33.37
34.38
Diluted EPS
-6.24
-53.22
10.53
33.37
34.38
Basic Average Shares
282,128.04
282,170.72
282,168.16
282,168.16
282,168.16
Diluted Average Shares
282,136.06
282,178.75
282,168.16
282,168.16
282,168.16
Rent Expense Supplemental
--
626,120
555,990
353,540
378,990
Total Expenses
111,415,060
110,043,830
103,530,640
103,341,500
90,899,900
Net Income from Continuing & Discontinued Operation
-1,758,350
-15,016,680
2,972,450
9,417,110
9,700,380
Normalized Income
1,238,225
-12,570,435
3,715,044
11,260,507.23
9,385,322
Interest Income
--
61,760
70,000
94,350
26,470
Interest Expense
2,889,120
5,159,690
3,490,360
2,980,990
3,531,130
Net Interest Income
-2,827,360
-5,097,930
-3,420,360
-2,886,640
-3,504,660
EBIT
22,109,740
5,524,640
5,888,780
17,393,450
17,355,880
EBITDA
27,231,160
11,832,740
12,001,460
22,260,600
21,791,420
Reconciled Cost of Revenue
47,255,940
48,790,420
45,866,050
47,781,710
39,966,250
Reconciled Depreciation
5,121,420
6,308,100
6,112,680
4,867,150
4,435,540
Net Income from Continuing Operation Net Minority Interest
-2,002,110
-18,989,960
-1,697,160
9,417,110
9,700,380
Total Unusual Items Excluding Goodwill
-4,629,050
-9,170,750
-7,731,720
-2,673,770
448,990
Total Unusual Items
-4,629,050
-9,170,750
-7,731,720
-2,673,770
448,990
Normalized EBITDA
31,860,210
21,003,490
19,733,180
24,934,370
21,342,430
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-1,388,715
-2,751,225
-2,319,516
-830,372.77
133,932
3/31/2021 - 2/10/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LUPIN.BO Lupin Limited
1,926.95
-4.23%
PARMAX.BO Parmax Pharma Limited
43.00
-0.58%
BAJAJHCARE.BO Bajaj HealthCare Limited
624.60
+0.44%
ANUHPHR.BO Anuh Pharma Limited
173.35
-0.43%
HIKAL.BO Hikal Limited
436.05
+5.22%
AARTIPHARM.BO Aarti Pharmalabs Limited
712.00
-0.05%
LAURUSLABS.BO Laurus Labs Limited
626.25
+0.14%
GLAND.BO Gland Pharma Limited
1,447.00
+1.43%
NEULANDLAB.BO Neuland Laboratories Limited
12,725.00
+0.55%
MANKIND.BO Mankind Pharma Limited
2,509.20
+3.35%